Spotlight on ENA 2024 News

The 36th EORTC-NCI-AACR (ENA) Symposium on Molecular Targets and Cancer Therapeutics continues to be a pivotal event for the global clinical cancer research community, fostering collaboration and innovation in the fight against cancer. The 36th edition has once again brought together world-leading scientists, clinicians, and industry experts to discuss the latest advancements in cancer therapeutics.

The event, held at the CCIB in Barcelona this week attracted over 1,200 participants from 41 countries. With a record number of abstract submissions since 2012, over 450 posters were presented at the ENA Symposium. Participants had the opportunity to hear from more than 60 international speakers and benefited from over 30 hours of educational sessions. The event was a hub for knowledge sharing and networking, making it an invaluable experience for all attendees.

Denis Lacombe, EORTC’s CEO said: “ENA is a critical meeting for discovering new emerging targets. It serves as a hub to delve deeper into the extensive knowledge within the field and explore how this can be translated into future treatments. We look forward to the 2025 edition in the USA led by AACR and we hope to welcome you all European edition in Barcelona, 18-20 November 2026, led by Elena Garralda”.

NEWS RELEASES

• New drug, WNTinib, delays tumour growth and improves survival in mouse models of children’s liver cancer
• Treatments used for HER2-positive breast cancers could help patients with rare gastrointestinal cancer
• New ‘mini-protein’ carries radiation dose directly to tumours without harming healthy tissues
• Researchers find key genetic mutations in bowel cancer cells that lead to resistance to WRN inhibitors
• Patients with advanced bladder cancer with alterations in the FGFR3 gene respond well to investigational drug, TYRA-300
• Scientists create cancer patients’ ‘digital twins’ to predict how well treatments may work